Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy

Abstract

These results demonstrate type 2 inflammation is an important contributor to the pathophysiology of AR disease and that inhibition of the type 2 pathway with dupilumab may normalize nasal tissue gene expression.